BGBarbara Giordani

Barbara Giordani

*This is an algorithmically generated author record based on publicly available information.

Barbara Giordani has a total of 27 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Reply to Gumustepe, A.; Gumustepe, E. Comment on “Giordani et al. Cancer Association in Patients with Immune-Mediated Inflammatory Diseases: A Five-Year Nationwide Italian Cohort Study. Cancers 2026, 18, 3449”

    by Barbara Giordani, Luigi Pirtoli, Guido Putignano, Antonio Giordano, Daniela Marotto, Giovanni Baglio

    We sincerely thank Gumustepe A

  • Top Cited Papers
    Open Access

    Cancer Association in Patients with Immune-Mediated Inflammatory Diseases: A Five-Year Nationwide Italian Cohort Study

    by Barbara Giordani, Luigi Pirtoli, Guido Putignano, Antonio Giordano, Daniela Marotto, Giovanni Baglio

    Background: Cancer represents a major concern in rheumatology. Epidemiological studies have demonstrated associations between rheumatic conditions and increased cancer risk at specific sites. However, comprehensive Italian epidemiological data on this association remain lacking. Methods: We conducted a nationwide retrospective cohort study using Italian Hospital Discharge Records from patients hospitalized between 1 January and 31 December 2018, with follow-up until 31 December 2023. Adult patients with Immune-mediated inflammatory diseases (IMID), including rheumatoid arthritis (RA) and diffuse diseases of connective tissue (DDCT), were the exposed group. The unexposed group included patients with primary diagnoses of injury and poisoning, with no IMID history. We used multivariable logistic regression models to assess cancer association, adjusting for demographics, geography, time of follow-up and comorbidities. Results: We included 54,896 IMID patients (exposed) and 301,126 unexposed. During the five-year follow-up, the IMID group was significantly associated with cancer (adjusted OR 1.32, 95% CI 1.27–1.38; p < 0.001). The ORadj decreased over time, from 1.83 (p < 0.001) in year one to 1.20 (p < 0.001) from the fifth year onward. Significant association with lung cancer (ORadj 1.74; p < 0.001), leukemia and lymphoma (ORadj 1.98; p < 0.001), bladder (ORadj 1.48; p < 0.001) and melanoma (ORadj 1.48; p = 0.009) were observed in the IMID group. DDCT patients showed an overall higher cancer risk (ORadj 1.53, p < 0.001) than RA patients (ORadj 1.20, p < 0.001). Conclusions: This first nationwide Italian study confirms an association with cancer in IMID patients, with the highest association in the first year post-diagnosis. The temporal decrease in cancer risk generates the hypothesis that inflammation, rather than medication, may be the primary driver. These findings support enhanced cancer surveillance in IMID patients, particularly during the first year after diagnosis.


  • Models for Assessing Hospital Care: The Experience of the Italian National Outcome Programme

    by Barbara Giordani, Erica Eugeni, Giorgia Duranti, Elisa Guglielmi, Alessandra Burgio, Giovanni Baglio, the PNE Working Group

  • Open Access

    The Use of ICD-9-CM Coding to Identify COVID-19 Diagnoses and Determine Risk Factors for 30-Day Death Rate in Hospitalized Patients in Italy: Retrospective Study

    by Barbara Giordani, Alessandra Burgio, Francesco Grippo, Alessandra Barone, Erica Eugeni, Giovanni Baglio

    Background: In Italy, it has been difficult to accurately quantify hospital admissions of patients with a COVID-19 diagnosis using the Hospital Information System (HIS), mainly due to the heterogeneity of codes used in the hospital discharge records during different waves of the COVID-19 pandemic. Objective: The objective of this study was to define a specific combination of codes to identify the COVID-19 hospitalizations within the HIS and to investigate the risk factors associated with mortality due to COVID-19 among patients admitted to Italian hospitals in 2020. Methods: A retrospective study was conducted using the hospital discharge records, provided by more than 1300 public and private Italian hospitals. Inpatient hospitalizations were detected by implementing an algorithm based on specific International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) code combinations. Hospitalizations were analyzed by different clinical presentations associated with COVID-19 diagnoses. In addition, 2 multivariable Cox regression models were performed among patients hospitalized “due to COVID-19” from January 1 to December 31, 2020, to investigate potential risk factors associated with 30-day death and the temporal changes over the course of the pandemic; in particular, the 30-day death rates during the first and the second waves were analyzed across 3 main geographical areas (North, Center, and South and Islands) and by discharge wards (ordinary and intensive care). Results: We identified a total of 325,810 hospitalizations with COVID-19–related diagnosis codes. Among these, 73.4% (n=239,114) were classified as “due to COVID-19,” 14.5% (n=47,416) as “SARS-CoV-2 positive, but not due to COVID-19,” and 12.1% (n=39,280) as “suspected COVID-19” hospitalizations. The cohort of patients hospitalized “due to COVID-19” included 205,048 patients, with a median age of 72 years and a higher prevalence of male patients (n=124,181, 60.6%). The overall 30-day death rate among hospitalized patients due to COVID-19 was 9.9 per 1000 person-days. Mortality was lower for women (hazard ratio [HR]=0.83; P<.001) and for patients coming from high migration pressure countries, especially Northern Africans (HR=0.65; P<.001) and Central and Eastern Europeans (HR=0.66; P<.001), compared to patients coming from Italy and high-income countries. In the southern regions and the Islands, mortality was higher compared to the northern regions (HR=1.17; P<.001), especially during the second wave of COVID-19 among patients with a transfer to intensive care units (HR=2.52; P<.001). Conclusions: To our knowledge, the algorithm is the first attempt to define, at a national level, selection criteria for identifying COVID-19 hospitalizations within the HIS. The implemented algorithm will be used to monitor the pandemic over time, and the patients selected in 2020 will be followed up in the next years to assess the long-term effects of COVID-19.


  • Open Access

    P279 IMPACT OF COVID–19 DIAGNOSIS ON HOSPITALIZATION AND MORTALITY RATES IN PATIENTS WITH ISCHEMIC STROKE ADMITTED DURING THE 2020 PANDEMIC IN ITALY

    by S Rosato, P D’ Errigo, B Giordani, F Seccareccia, G Badoni, A Tavilla, G Mureddu, L De Luca, G Baglio

    And purpose. We sought to evaluate the impact of the Covid–19 infection on hospitalization and mortality rates in patients with ischemic stroke admitted during the 2020 pandemic in Italy. We analysed a nationwide, comprehensive, and universal administrative database of consecutive patients admitted for ischemic stroke during and after the national lockdown for Covid–19 infection in 2020 and the equivalent periods of the previous 5 years in Italy. The 2020 observed rates of hospitalizations and mortality of stroke patients with and without Covid–19 infection were compared with the expected rates, according to the trend of the previous 5 years. During the period of observation, 300,890 hospitalizations for ischemic stroke occurred in Italy. In 2020, 41,302 stroke patients (1102 with concomitant Covid–19 infection) were admitted at 771 centers. The rate of admissions for ischemic stroke during the 2020 pandemic was markedly reduced compared to the previous years (percentage change –23.5). Based on the 5–year trend, the 2020 expected rate of 30–day and 1–year mortality was 9.8% and 23.9%, while the observed incidence of death was 12.2% and 26.7%, respectively (both p<0.001). After multiple corrections, the higher rate of mortality was observed among patients admitted for stroke with a concomitant Covid–19 diagnosis. During the Covid–19 pandemic in 2020 in Italy, the rate of hospitalizations for ischemic stroke was dramatically reduced, while both 30–day and 1–year mortality was increased, especially in those with a Covid–19 diagnosis, compared to the previous 5–year trend.

  • Open Access

    Impact of COVID-19 Diagnosis on Mortality in Patients with ST-Elevation Myocardial Infarction Hospitalized during the National Outbreak in Italy

    by Leonardo De Luca, Stefano Rosato, Paola D’errigo, Barbara Giordani, Gian Francesco Mureddu, Gabriella Badoni, Fulvia Seccareccia, Giovanni Baglio

    Background. We sought to assess the clinical impact of COVID-19 infection on mortality in patients with ST-elevation myocardial infarction (STEMI) admitted during the national outbreak in Italy. Methods. We analysed a nationwide, comprehensive, and universal administrative database of consecutive STEMI patients admitted during lockdown for COVID-19 infection (11 March–3 May 2020) and the equivalent periods of the previous 5 years in Italy. The observed rate of 30-day and 6-month all-cause mortality of STEMI patients with and without COVID-19 infection during the lockdown was compared with the expected rate of death, according to the trend of the previous 5 years. Results. During the study period, 32.910 STEMI hospitalizations occurred in Italy. Among these, 4048 STEMI patients were admitted during the 2020 outbreak: 170 (4.2%) with and 3878 (95.8%) without a COVID-19 diagnosis. According to the 5-year trend, the 2020 expected rates of 30-day and 6-month all-cause mortality were 9.2% and 12.6%, while the observed incidences of death were 10.8% (p = 0.016) and 14.4% (p = 0.017), respectively. Excluding STEMI patients with a COVID-19 diagnosis, the mortality rate resulted in accordance with the prior 5-year trend. After multiple corrections, the presence of COVID-19 diagnosis was an independent predictor of all-cause mortality at 30 days [adjusted odds ratio (OR) 4.5; 95% confidence intervals (CI) 3.09–6.45; p < 0.0001] and 6 months (adjusted OR 3.6; 95% CI: 2.47–5.12; p < 0.0001). Conclusions.During the 2020 national outbreak in Italy, COVID-19 infection significantly increased the mortality trend in patients with STEMI.


  • Open Access

    The Use of ICD-9-CM Coding to Identify COVID-19 Diagnoses and Determine Risk Factors for 30-Day Death Rate in Hospitalized Patients in Italy: Retrospective Study (Preprint)

    by Barbara Giordani, Alessandra Burgio, Francesco Grippo, Alessandra Barone, Erica Eugeni, Giovanni Baglio

    BACKGROUND In Italy, it has been difficult to accurately quantify hospital admissions of patients with a COVID-19 diagnosis using the Hospital Information System (HIS), mainly due to the heterogeneity of codes used in the hospital discharge records during different waves of the COVID-19 pandemic. OBJECTIVE The objective of this study was to define a specific combination of codes to identify the COVID-19 hospitalizations within the HIS and to investigate the risk factors associated with mortality due to COVID-19 among patients admitted to Italian hospitals in 2020. METHODS A retrospective study was conducted using the hospital discharge records, provided by more than 1300 public and private Italian hospitals. Inpatient hospitalizations were detected by implementing an algorithm based on specific International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) code combinations. Hospitalizations were analyzed by different clinical presentations associated with COVID-19 diagnoses. In addition, 2 multivariable Cox regression models were performed among patients hospitalized “due to COVID-19” from January 1 to December 31, 2020, to investigate potential risk factors associated with 30-day death and the temporal changes over the course of the pandemic; in particular, the 30-day death rates during the first and the second waves were analyzed across 3 main geographical areas (North, Center, and South and Islands) and by discharge wards (ordinary and intensive care). RESULTS We identified a total of 325,810 hospitalizations with COVID-19–related diagnosis codes. Among these, 73.4% (n=239,114) were classified as “due to COVID-19,” 14.5% (n=47,416) as “SARS-CoV-2 positive, but not due to COVID-19,” and 12.1% (n=39,280) as “suspected COVID-19” hospitalizations. The cohort of patients hospitalized “due to COVID-19” included 205,048 patients, with a median age of 72 years and a higher prevalence of male patients (n=124,181, 60.6%). The overall 30-day death rate among hospitalized patients due to COVID-19 was 9.9 per 1000 person-days. Mortality was lower for women (hazard ratio [HR]=0.83; P<.001) and for patients coming from high migration pressure countries, especially Northern Africans (HR=0.65; P<.001) and Central and Eastern Europeans (HR=0.66; P<.001), compared to patients coming from Italy and high-income countries. In the southern regions and the Islands, mortality was higher compared to the northern regions (HR=1.17; P<.001), especially during the second wave of COVID-19 among patients with a transfer to intensive care units (HR=2.52; P<.001). CONCLUSIONS To our knowledge, the algorithm is the first attempt to define, at a national level, selection criteria for identifying COVID-19 hospitalizations within the HIS. The implemented algorithm will be used to monitor the pandemic over time, and the patients selected in 2020 will be followed up in the next years to assess the long-term effects of COVID-19.

  • Open Access

    The National Outcomes Evaluation Programme in Italy: The Impact of Publication of Health Indicators

    by Paola Colais, Luigi Pinnarelli, Francesca Mataloni, Barbara Giordani, Giorgia Duranti, Paola D’errigo, Stefano Rosato, Fulvia Seccareccia, Giovanni Baglio, Marina Davoli

    In Italy the National Outcomes Evaluation Programme, (P.N.E.) is the most comprehensive comparative evaluation of healthcare outcomes at the national level. The aim of this report is to describe the P.N.E. and some of the most relevant results achieved. The P.N.E. analysed 184 indicators on quality of care in 2015–2020 period. The data sources are the Italian Health Information Systems. The indicators reported were: proportion of surgery within 2 days after hip fracture in the elderly (HF), 30-day mortality after hospital admission for acute myocardial infarction (AMI), proportion of reoperations within 90 days of breast-conserving surgery and proportion of primary caesarean deliveries. Risk adjustment methods were used to take into account patients’ characteristics. From 2010 to 2020 the proportion of interventions within 2 days after HF increased from 31.3% to 64.6%, the AMI 30-day mortality decreased from 10.4% to 8.3%, the proportion of reinterventions within 90 days of breast-conserving surgery decreased from 12.0% to 5.9% and the proportion of primary caesarean deliveries decreased from 28.4% to 22.7%. Results by area of residence showed heterogeneity of healthcare quality. We observed a general improvement in different clinical areas not always associated with a reduction of heterogeneity among areas of residence.